Please login to the form below

Not currently logged in

infectious diseases

This page shows the latest infectious diseases news and features for those working in and with pharma, biotech and healthcare.

Gilead poaches Genentech-exec Merdad Parsey for its new CMO

Gilead poaches Genentech-exec Merdad Parsey for its new CMO

His clinical expertise and experience across a number of therapeutic areas, including inflammation, oncology and infectious diseases will be particularly useful as Gilead continues to stake its claim in these markets.

Latest news

More from news
Approximately 4 fully matching, plus 174 partially matching documents found.

Latest Intelligence

  • Biotech profile: Tom Evans, CEO, Vaccitech.

    He moved to the University of Rochester as Associate Professor for 5 years, before becoming Infectious Diseases Division Chief and tenured full Professor at the University of California, Davis. ... In 2005, he joined the Novartis Institutes for

  • The threat of antimicrobial resistance The threat of antimicrobial resistance

    A study recently reported in The Lancet Infectious Diseases found that antibiotics are now failing to work in a fifth of patients who suffer an infection after hospital surgery.

  • Deal Watch February 2016 Deal Watch February 2016

    Alere has annual sales of approximately $2.5bn from a portfolio of point-of-care products in areas including cardiometabolic, infectious diseases such as HIV, malaria, syphilis, E. ... Pronutria's focus is on the development of therapeutics and

  • Searching for health Searching for health

    year. The pharma work is organised into therapeutic areas covering cancers, infectious diseases, immunology, cardiovascular and metabolism diseases with each having dedicated research teams managing all aspects - from finding new compounds

  • The world is our laboratory The world is our laboratory

    Our goal is to improve patient outcomes in the most serious unmet medical needs of our time, including neglected diseases. ... Focused specialties. At Janssen, we have focused our research into five important therapeutic areas: Cardiovascular &Metabolic

More from intelligence
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 36 partially matching documents found.

Latest from PMHub

  • emotive adds to medical team with new Scientific Lead and Associate Medical Writer

    Following a busy year and with a number of new Global and EMEA account wins including two pre-launch products for rare diseases, emotive has strengthened the medical team with the ... in rare diseases such as Gaucher disease and Cushing’s disease

  • Australian Flu and the dilemma of naming diseases

    In recent times, the potentially damaging consequences of ‘naming’ infectious diseases have been identified, and in 2015 the World Health Organisation (WHO) introduced its ‘Best Practices for the Naming of New ... Human Infectious Diseases’,


    cardiovascular disease. diabetes. women’s health. nutrition. allergy. infectious diseases. wound care.

  • New insights into making behavioural change work

    The focus of pharmacological interventions has experienced a shift over recent years, with a greater emphasis placed on addressing lifestyle conditions than on fighting infectious diseases. ... Lifestyle conditions, or noncommunicable diseases (NCDs),

  • To track disease, follow the money

    Contrast this with the slow march of infectious diseases before the era of mass movement and jet travel. ... But banknotes do not spread or reproduce like infectious agents, more's the pity, nor does the movement of money accurately reproduce the

More from PMHub
Approximately 1 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...